 ATLANTA, Aug. 24, 2021 GLOBE NEWSWIRE -- Alimera Sciences, Inc. NASDAQ: ALIM Alimera, a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN for diabetic macular edema DME in Belgium from the National Institute for Health and Disability Insurance INAMI. Pricing and reimbursement approval was sought and secured by Alimeras distribution partner in France and the Benelux region, Horus Pharma S.A.S. Horus. Horus is currently in the launch phase in Belgium. 